Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I Trial of TQB3915 in Advanced Solid Tumors
NCT05416359Phase 1Unknown
- Sponsor
- Chia Tai-Tianqing Pharmaceutical Group
- Start
- Jun 2022
- Primary completion
- Jun 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of TQB3915 in Advanced Malignant Solid Neoplasm (AMSN), sponsored by Chia Tai-Tianqing Pharmaceutical Group. Primary endpoints: Dose-Limiting Toxicity up to 7 months, Maximum Tolerated Dose up to 7 months and 1 more. Status: unknown.
02
Drugs
TQB3915
03
Conditions
Advanced Malignant Solid Neoplasm (AMSN)
Beyond the preview
Go deeper on NCT05416359.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05416359.